GuineaTuberculosis profile
Population  2016 12 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.3 (1.9–4.9) 26 (16–40)
Mortality (HIV+TB only) 2 (1.3–2.9) 16 (10–23)
Incidence  (includes HIV+TB) 22 (14–31) 176 (114–252)
Incidence (HIV+TB only) 5.4 (3.4–7.8) 43 (28–63)
Incidence (MDR/RR-TB)** 0.73 (0.14–1.3) 5.9 (1.1–11)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.3 (0.78–1.8) 7 (4.3–9.8) 8.3 (5.1–12)
Males 1.5 (0.89–2) 12 (7.3–17) 14 (8.2–19)
Total 2.8 (1.7–3.8) 19 (12–27) 22 (14–31)
TB case notifications, 2016  
Total cases notified 12 872
Total new and relapse 12 639
          - % tested with rapid diagnostics at time of diagnosis 13%
          - % with known HIV status 82%
          - % pulmonary 78%
          - % bacteriologically confirmed among pulmonary 81%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 58% (40–89)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.25 (0.14–0.38)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 2 539 25%
          - on antiretroviral therapy 1 800 71%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  360
(96–630)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance 17% 47% 2 421
MDR/RR-TB cases tested for resistance to second-line drugs   26
Laboratory-confirmed cases MDR/RR-TB: 178, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 137, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 80% 12 154
Previously treated cases, excluding relapse, registered in 2015 76% 88
HIV-positive TB cases registered in 2015 74% 2 332
MDR/RR-TB cases started on second-line treatment in 2014 75% 123
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
36% (33–39)
TB financing, 2017  
National TB budget (US$ millions) 3.8
Funding source: 4% domestic, 71% international, 24% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data